2,3,4-trihydroxy-benzoic acid hydrazide | 918441-21-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3,4-trihydroxy-benzoic acid hydrazide
• 英文别名: 2,3,4-Trihydroxy-benzoesaeure-hydrazid；2,3,4-Trihydroxybenzohydrazide
• CAS: 918441-21-1
• 化学式: C₇H₈N₂O₄
• 分子量: 184.152
• InChiKey: JYGGOAOSKPLGQF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  116
• 氢给体数：
  5
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,3,4-trihydroxy-benzoic acid hydrazide 、 水杨醛 在 sodium hydroxide 作用下， 生成 2,3,4-trihydroxy-benzoic acid salicylidenehydrazide
  参考文献：
  名称：

  Über das Diäthoxy-dulcin, das Diäthoxy-phenazetin und einige andere Derivate des Pyrogallols

  摘要：

  DOI：

  10.1002/ardp.19342721009
• 作为产物：
  描述：

  methyl 2,3,4-trihydroxybenzoate 在 一水合肼 作用下， 生成 2,3,4-trihydroxy-benzoic acid hydrazide
  参考文献：
  名称：

  Über das Diäthoxy-dulcin, das Diäthoxy-phenazetin und einige andere Derivate des Pyrogallols

  摘要：

  DOI：

  10.1002/ardp.19342721009

文献信息

• PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS
  申请人：TenNor Therapeutics Limited

  公开号：US20210070774A1

  公开（公告）日：2021-03-11

  Novel iron chelating group conjugated penam derivatives described herein show antibacterial activity, and could be used as antibacterial agents or beta-lactamase inhibitors (BLIs) which are of value for application in combination with other antibacterial agents.

  本文描述的新型铁螯合基团共轭的青霉素衍生物表现出抗菌活性，可用作抗菌剂或β-内酰胺酶抑制剂（BLIs），与其他抗菌剂联合应用具有价值。
• Novel <i>N</i>‐pyrocatechoyl and <i>N</i>‐pyrogalloyl hydrazone antioxidants endowed with cytotoxic and antibacterial activity
  作者：Jovica Branković、Vesna Matejić、Dušica Simijonović、Milena D. Vukić、Miroslava Kačaniova、Marko Živanović、Ana Mirić、Jelena Košarić、Marija Branković、Vladimir P. Petrović

  DOI：10.1002/ardp.202300725

  日期：——

  Over the years, pharmacological agents bearing antioxidant merits arose as beneficial in the prophylaxis and treatment of various health conditions. Hazardous effects of radical species hyperproduction disrupt normal cell functioning, thus increasing the possibility for the development of various oxidative stress‐associated disorders, such as cancer. Contributing to the efforts for efficient antioxidant drug discovery, a thorough in vitro and in silico assessment of antioxidant properties of 14 newly synthesized N‐pyrocatechoyl and N‐pyrogalloyl hydrazones (N‐PYRs) was accomplished. All compounds exhibited excellent antioxidant potency against the 2,2‐diphenyl‐1‐picrylhydrazyl (DPPH) radical. The extensive in silico analysis revealed multiple favorable features of N‐PYRs to inactivate harmful radical species, which supported the obtained in vitro results. Also, in silico experiments provided insights into the preferable antioxidant pathways. Prompted by these findings, the cytotoxicity effects and the influence on the redox status of cancer HCT‐116 cells and healthy fibroblasts MRC‐5 were evaluated. These investigations exposed four analogs exhibiting both cytotoxicity and selectivity toward cancer cells. Furthermore, the frequently uncovered antimicrobial potency of hydrazone‐type hybrids encouraged investigations on G⁺ and G^– bacterial strains, which revealed the antibacterial potency of several N‐PYRs. These findings highlighted the N‐PYRs as excellent antioxidant agents endowed with cytotoxic and antibacterial features.

  摘要 多年来，具有抗氧化作用的药剂在预防和治疗各种健康问题方面发挥了有益的作用。自由基过量产生的有害影响破坏了细胞的正常功能，从而增加了癌症等各种氧化应激相关疾病发生的可能性。为了促进高效抗氧化药物的发现，我们对 14 种新合成的 N-对儿茶酸酰和 N-焦醛酰肼（N-PYRs）的抗氧化特性进行了全面的体外和硅学评估。所有化合物对 2,2-二苯基-1-苦基肼（DPPH）自由基都表现出卓越的抗氧化效力。大量的硅学分析揭示了 N-PYRs 在灭活有害自由基物种方面的多种有利特征，这为体外实验结果提供了支持。此外，硅学实验还揭示了抗氧化的最佳途径。在这些发现的推动下，研究人员对 HCT-116 癌细胞和 MRC-5 健康成纤维细胞的细胞毒性作用及其对氧化还原状态的影响进行了评估。这些研究揭示了四种对癌细胞具有细胞毒性和选择性的类似物。此外，经常发现的腙类杂交化合物的抗菌效力鼓励了对 G+ 和 G- 细菌菌株的研究，从而揭示了几种 N-PYR 的抗菌效力。这些发现突出表明，N-PYR 是具有细胞毒性和抗菌特性的优秀抗氧化剂。
• DEUTERATED CATECHOLAMINE DERIVATIVES AND MEDICAMENTS COMPRISING SAID COMPOUNDS
  申请人：ratiopharm GmbH

  公开号：EP3101001A1

  公开（公告）日：2016-12-07

  The present invention concerns deuterated catecholamine derivatives of formula (I) as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically acceptable salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as other disorders.

  本发明涉及式（I）的氚代儿茶酚胺衍生物以及含有这些化合物的药物。此外，本发明还涉及氘代儿茶酚胺衍生物及其生理上可接受的盐类，以及含有这些化合物的药物组合物（也可与酶抑制剂结合使用），用于治疗多巴胺缺乏症或基于酪氨酸转运紊乱或酪氨酸脱羧酶紊乱的疾病，以及其他疾病。
• Penam derivatives for treating bacterial infections
  申请人：TenNor Therapeutics Limited

  公开号：US11040987B2

  公开（公告）日：2021-06-22

  Novel iron chelating group conjugated penam derivatives described herein show antibacterial activity, and could be used as antibacterial agents or beta-lactamase inhibitors (BLIs) which are of value for application in combination with other antibacterial agents.

  本文所述的新型铁螯合基团共轭五氯化萘衍生物具有抗菌活性，可用作抗菌剂或β-内酰胺酶抑制剂（BLIs），具有与其他抗菌剂联合应用的价值。
• SCHMERZPRÄPARAT
  申请人：KAMPRAD, Joachim

  公开号：EP0344158B1

  公开（公告）日：1992-04-08